ENTX

Entera is a clinical-stage drug developer, not an operating business: FY2025 'revenue' of $42.0K (down 76.8%) is grant/collaboration noise, gross profit is $0, and the company states plainly in its 10-K that it 'has not generated any revenue from sales of our products' and won't until it wins regulatory approval. The headline valuation ratios are therefore meaningless — a P/S of 1,831x against negligible revenue, and a P/E of 6.6 built on a reported diluted EPS of $0.25 that cannot be reconciled with a -$11.4M net loss (the EPS sign is almost certainly a data artifact and should be treated as negative). The only honest way to value ENTX is as a binary pipeline bet, and the data here does not support a price target.

The decisive issue is the balance sheet against the burn. Operating cash flow was -$7.37M in FY2025 and the net loss widened 19.9% to -$11.4M while R&D rose 33.5% to $6.0M — and management guides that R&D 'will increase significantly in future periods.' The 10-K discloses cash of $12.6M as of March 23, 2026, but $7.8M of that is contractually designated for the OPKO collaboration, leaving only ~$4.8M of truly discretionary cash. Management explicitly states existing resources last only 'through the middle of the third quarter of 2026, excluding the Phase 3 study of EB613' — i.e., a runway that effectively expires within weeks of today (June 30, 2026). The pivotal Phase 3 of EB613 in osteoporosis 'will require additional funding, which may not be available on reasonable terms, or at all,' and 'any delay or our inability to secure such funding will delay or prevent' the study. That is a financing cliff layered on top of clinical risk.